• Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral  milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.

• Endoh M. Mechanism of action of Ca2+ sensitizers--update 2001. Cardiovascular Drugs & Therapy 2001:15;397-403.

• Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opinion on Investigational Drugs 2001: 10;955-70.

• Kersten JR, Montgomery MW, Pagel PS, Warltier DC.Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg. 2000Jan;90(1):5-11.

• Sonntag S et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia.J Am Coll Cardiol 2004;43:2177-2182.

• Pataricza J et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery.Cardiovasc Drugs Ther 2003; 17:115-21

• Maytin M et. al. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Am J Cardiol 2005; 96: 26G-31G.

• Follath F, Hinkka S, Jager D, et al. Dose-ranging and safety with intravenous levosimendan in low-output Herat failure: experience in three pilot studies and outline of the levosimendan infusión versus dobutamine (LIDO) trial. Am J Caidiol. 1999; 83(supl 12B): 21-25.

• Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000; 102: 2222-2227.

• Moiseyev VS, Poder P, Andrejevs N, et. al. Safety and efficacy of a novel calcium sensitizer,levosimendan, in patiens with left ventricular failure due to an acute myocardial infarction (RUSSLAN). Eur. Heart J 2002; 23: 1422-1432.

• Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a ramdomised doubleblind trial. The Lancet 2002; 360: 196-202.

• Lehtonen L. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Curr Heart Fail Rep. 2004;1:136-44

• Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH,SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiacresynchronisation therapy in heart failure. Eur J Heart Fail. 2004 Jun;6:501-8.

• Teerlink JR. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol. 2005 Sep 19;96(6A):59G-67G.